Abstract
In recent years, computational cardiac electrophysiology simulations using mathematical models have begun to be used in industrial and regulatory assessment of the proarrhythmic risk of candidate drug compounds. The aim of this chapter is to equip the reader with the background necessary to critically engage with academic journal articles and reports on this topic. We provide an introduction to the basis for these models, discuss how compound action is modeled, and examine the simulated emergent properties that can correlate with proarrhythmic risk. We discuss important principles around uncertainty, how to assess simulation reliability and reproducibility, and therefore how to establish trust in model predictions. We examine applications of simulations to date, particularly in the context of the comprehensive in vitro proarrhythmia Assay (CiPA). The chapter concludes with a discussion of future avenues for research.
This is a preview of subscription content, log in via an institution to check access.
References and Further Reading
Abildskov J, Lux RL (1991) The mechanism of simulated torsade de pointes in a computer model of propagated excitation. J Cardiovasc Electrophysiol 2(3):224–237. https://doi.org/10.1111/j.1540-8167.1991.tb01321.x
Agrawal A, Wang K, Polonchuk L, Cooper J, Mirams GR, Gavaghan DJ, Clerx M (2022) Models of the cardiac L-type calcium current: a quantitative comparison. WIREs Mech Dis. https://doi.org/10.1002/wsbm.1581
Alexander C, Bishop M, Gilchrist R, Burton F, Smith G, Myles R (2022) Initiation of ventricular arrhythmia in the acquired long QT syndrome. Cardiovasc Res. https://doi.org/10.1093/cvr/cvac103
Ballou LM, Lin RZ, Cohen IS (2015) Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels. Circ Res 116(1):127–137. https://doi.org/10.1161/CIRCRESAHA.116.303975
Beattie KA, Luscombe C, Williams G, Munoz-Muriedas J, Gavaghan DJ, Cui Y, Mirams GR (2013) Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods 68(1):88–96. https://doi.org/10.1016/j.vascn.2013.04.004
Beattie KA, Hill AP, Bardenet R, Cui Y, Vandenberg JI, Gavaghan DJ, de Boer TP, Mirams GR (2018) Sinusoidal voltage protocols for rapid characterisation of ion channel kinetics. J Physiol 596(10):1813–1828. https://doi.org/10.1113/JP275733
Becker N, Horváth A, De Boer T, Fabbri A, Grad C, Fertig N, George M, Obergrussberger A (2020) Automated dynamic clamp for simulation of IK1 in human induced pluripotent stem cell–derived cardiomyocytes in real time using Patchliner Dynamite8. Curr Protocols Pharmacol 88(1):1–23. https://doi.org/10.1002/cpph.70
Bennette C, Vickers A (2012) Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol 12(1):21. https://doi.org/10.1186/1471-2288-12-21
Black JW (1988) Drugs from emasculated hormones: the principles of syntopic antagonism. Nobel Prize for Physiology or Medicine Lecture, Karolinska Institute. https://www.nobelprize.org/prizes/medicine/1988/black/lecture/. Accessed 12 Oct 2022
Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26(3):585–615. https://doi.org/10.1111/j.1744-7348.1939.tb06990.x
Bottino D, Penland R, Stamps A, Traebert M, Dumotier B, Georgeva A, Helmlinger G, Lett G (2006) Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol 90(1-3):414–443. https://doi.org/10.1016/j.pbiomolbio.2005.06.006
Braakman S, Pathmanathan P, Moore H (2022) Evaluation framework for systems models. PCPT Pharm Syst Pharmacol 11(3):264–289. https://doi.org/10.1002/psp4.12755
Brennan T, Fink M, Rodríguez B (2009) Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur J Pharm Sci 36(1):62–77. https://doi.org/10.1016/j.ejps.2008.09.013
Britton OJ, Abi-Gerges N, Page G, Ghetti A, Miller PE, Rodriguez B (2017) Quantitative comparison of effects of dofetilide, sotalol, quinidine, and verapamil between human ex vivo trabeculae and in silico ventricular models incorporating inter-individual action potential variability. Front Physiol 8:1–19. https://doi.org/10.3389/fphys.2017.00597
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, Bub G, Channon K, Paterson DJ, Terrar DA, Burton RAB (2015) Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current if: novel electrophysiological insights and therapeutic potential. Heart Rhythm 12(10):2186–2194. https://doi.org/10.1016/j.hrthm.2015.05.027
Chang KC, Dutta S, Mirams GR, Beattie KA, Sheng J, Tran PN, Wu M, Wu WW, Colatsky T, Strauss DG, Li Z (2017) Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment. Front Physiol 8:1–17. https://doi.org/10.3389/fphys.2017.00917
Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, Bar-Cohen R, Kogan E, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Stefano C, Chinitz LA, Jankelson L (2020) QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm 17(9):1425–1433. https://doi.org/10.1016/j.hrthm.2020.05.014
Christophe B (2022) Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: in silico study using 109 torsadogenic or non-torsadogenic compounds. Toxicol Appl Pharmacol 438:115914. https://doi.org/10.1016/j.taap.2022.115914
Clark AP, Wei S, Kalola D, Krogh-Madsen T, Christini DJ (2022) An in silico–in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms. Br J Pharmacol. https://doi.org/10.1111/bph.15915
Clerx M, Beattie KAK, Gavaghan DDJ, Mirams GR (2019) Four ways to fit an ion channel model. Biophys J 117(12):2420–2437. https://doi.org/10.1016/j.bpj.2019.08.001
Cooper J, Mirams GR, Niederer SA (2011) High-throughput functional curation of cellular electrophysiology models. Prog Biophys Mol Biol 107(1):11–20. https://doi.org/10.1016/j.pbiomolbio.2011.06.003
Cooper J, Spiteri RJ, Mirams GR (2015) Cellular cardiac electrophysiology modeling with chaste and cellML. Front Physiol 5:511
Cooper J, Scharm M, Mirams GR (2016) The cardiac electrophysiology web lab. Biophys J 110(2):292–300. https://doi.org/10.1016/j.bpj.2015.12.012
Cummins Lancaster M, Sobie E (2016) Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms. Clin Pharmacol Ther 100(4):371–379. https://doi.org/10.1002/cpt.367
Davies MR, Mistry HB, Hussein L, Pollard CE, Swinton J, Valentin JPJP, Abi-Gerges N (2012) An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am J Physiol Heart Circ Physiol 302(7):H1466–H1480. https://doi.org/10.1152/ajpheart.00808.2011
Davies MR, Wang K, Mirams GR, Caruso A, Noble D, Walz A, Lavé T, Schuler F, Singer T, Polonchuk L (2016) Recent developments in using mechanistic cardiac modelling for drug safety evaluation. Drug Discov Today 21(6):924–938. https://doi.org/10.1016/j.drudis.2016.02.003
Davies MR, Martinec M, Walls R, Schwarz R, Mirams GR, Wang K, Steiner G, Surinach A, Flores C, Lavé T, Singer T, Polonchuk L (2020) Use of patient health records to quantify drug-related pro-arrhythmic risk. Cell Rep Med 1(5):100076. https://doi.org/10.1016/j.xcrm.2020.100076
Delaunois A, Abernathy M, Anderson WD, Beattie KA, Chaudhary KW, Coulot J, Gryshkova V, Hebeisen S, Holbrook M, Kramer J, Kuryshev Y, Leishman D, Lushbough I, Passini E, Redfern WS, Rodriguez B, Rossman EI, Trovato C, Wu C, Valentin J (2021) Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19. Clin Transl Sci 14(3):1133–1146. https://doi.org/10.1111/cts.13011
Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR (2013) High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. PAJP Heart Circ Physiol 304(1):H104–H117. https://doi.org/10.1152/ajpheart.00511.2012
Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR (2014) hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment. J Cardiovasc Electrophysiol 25(2):197–207. https://doi.org/10.1111/jce.12289
Dunnink A, Stams TR, Bossu A, Meijborg VM, Beekman JD, Wijers SC, De Bakker JM, Vos MA (2016) Torsade de pointes arrhythmias arise at the site of maximal heterogeneity of repolarization in the chronic complete atrioventricular block dog. Europace 19(5):euw087. https://doi.org/10.1093/europace/euw087
Dutta S, Chang KC, Beattie KA, Sheng J, Tran PN, Wu WW, Wu M, Strauss DG, Colatsky T, Li Z (2017) Optimization of an in silico cardiac cell model for proarrhythmia risk assessment. Front Physiol 8:616. https://doi.org/10.3389/fphys.2017.00616
Elkins RCRCR, Davies MRMR, Brough SJSJ, Gavaghan DJDJ, Cui Y, Abi-Gerges N, Mirams GRGR (2013) Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. J Pharmacol Toxicol Methods 68(1):112–122. https://doi.org/10.1016/j.vascn.2013.04.007
El-Sherif N, Caref EB, Yin H, Restivo M (1996) The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Circ Res 79(3):474–492. https://doi.org/10.1161/01.RES.79.3.474
Fermini B, Hancox JC, Abi-Gerges N, Bridgland-Taylor M, Chaudhary KW, Colatsky T, Correll K, Crumb W, Damiano B, Erdemli G, Gintant G, Imredy J, Koerner J, Kramer J, Levesque P, Li Z, Lindqvist A, Obejero-Paz CA, Rampe D, Sawada K, Strauss DG, Vandenberg JI (2016) A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen 21(1):1–11. https://doi.org/10.1177/1087057115594589
Fogli Iseppe A, Ni H, Zhu S, Zhang X, Coppini R, Yang P, Srivatsa U, Clancy CE, Edwards AG, Morotti S, Grandi E (2021) Sex-specific classification of drug-induced torsade de pointes susceptibility using cardiac simulations and machine learning. Clin Pharmacol Ther 110(2):380–391. https://doi.org/10.1002/cpt.2240
Furutani K, Tsumoto K, Chen IS, Handa K, Yamakawa Y, Sack JT, Kurachi Y (2019) Facilitation of IKr current by some hERG channel blockers suppresses early afterdepolarizations. J Gen Physiol 151(2):214–230. https://doi.org/10.1085/jgp.201812192
Garfinkel A, Kim YH, Voroshilovsky O, Qu Z, Kil JR, Lee MH, Karagueuzian HS, Weiss JN, Chen PS (2000) Preventing ventricular fibrillation by flattening cardiac restitution. Proc Natl Acad Sci 97(11):6061–6066. https://doi.org/10.1073/pnas.090492697
Garny A, Nickerson DP, Cooper J, Santos RWD, Miller AK, McKeever S, Nielsen PM, Hunter PJ (2008) CellML and associated tools and techniques. Philos Trans R Soc A Math Phys Eng Sci 366(1878):3017–3043. https://doi.org/10.1098/rsta.2008.0094
Gaur N, Ortega F, Verkerk AO, Mengarelli I, Krogh-Madsen T, Christini DJ, Coronel R, Vigmond EJ (2020) Validation of quantitative measure of repolarization reserve as a novel marker of drug induced proarrhythmia. J Mol Cell Cardiol 145:122–132. https://doi.org/10.1016/j.yjmcc.2020.04.019
Gomis-Tena J, Brown BM, Cano J, Trenor B, Yang PC, Saiz J, Clancy CE, Romero L (2020) When does the IC50Accurately assess the blocking potency of a drug? J Chem Inf Model 60(3):1779–1790. https://doi.org/10.1021/acs.jcim.9b01085
Gong JQX, Sobie EA (2018) Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types. npj Syst Biol Appl 4(1):11. https://doi.org/10.1038/s41540-018-0047-2
Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P (2008) The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 22(6):633–648. https://doi.org/10.1111/j.1472-8206.2008.00633.x
Grandi E, Pasqualini FS, Bers DM (2010) A novel computational model of the human ventricular action potential and Ca transient. J Mol Cell Cardiol 48(1):112–121. https://doi.org/10.1016/j.yjmcc.2009.09.019
Heitmann S, Shpak A, Vandenberg JI, Hill AP (2021) Arrhythmogenic effects of ultra-long and bistable cardiac action potentials. PLoS Comput Biol 17(2):e1008683. https://doi.org/10.1371/journal.pcbi.1008683
Hendrix M, Clerx M, Tamuri AU, Keating SM, Johnstone RH, Cooper J, Mirams GR, Nickerson D (2022) cellmlmanip and chaste_codegen: automatic CellML to C++ code generation with fixes for singularities and automatically generated Jacobians. Wellcome Open Res 6:261. https://doi.org/10.12688/wellcomeopenres.17206.2
Hill AV (1910) The possible effects of the aggregation of the molecules of hæmoglobin on its dissociation curves. J Physiol 40(Suppl):iv–vii. https://doi.org/10.1113/jphysiol.1910.sp001386
Hill A, Perry M, Abi-Gerges N, Couderc JP, Fermini B, Hancox J, Knollmann B, Mirams G, Skinner J, Zareba W, Vandenberg J (2016) Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century. J Physiol 594(23). https://doi.org/10.1113/JP272015
Hodgkin AL, Huxley AF (1952) A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 117(4):500
Hondeghem LM (1987) Antiarrhythmic agents: modulated receptor applications. Circulation 75(3):514–520. https://doi.org/10.1161/01.CIR.75.3.514
Hondeghem LM (2006) Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-Wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 17(3):337–340. https://doi.org/10.1111/j.1540-8167.2006.00347.x
Hondeghem LM, Katzung BG (1984) Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 24(1):387–423. https://doi.org/10.1146/annurev.pa.24.040184.002131
Jæger KH, Charwat V, Charrez B, Finsberg H, Maleckar MM, Wall S, Healy KE, Tveito A (2020) Improved computational identification of drug response using optical measurements of human stem cell derived cardiomyocytes in microphysiological systems. Front Pharmacol 10:1–24. https://doi.org/10.3389/fphar.2019.01648
Johnstone RH, Bardenet R, Gavaghan DJ, Mirams GR (2016) Hierarchical Bayesian inference for ion channel screening dose-response data. Wellcome Open Res 1:6. https://doi.org/10.12688/wellcomeopenres.9945.1
Keener J, Sneyd J (2009) Mathematical physiology: volume I: cellular physiology. Springer, New York
Kemp JM, Whittaker DG, Venkateshappa R, Pang Z, Johal R, Sergeev V, Tibbits GF, Mirams GR, Claydon TW (2021) Electrophysiological characterization of the hERG R56Q LQTS variant and targeted rescue by the activator RPR260243. J Gen Physiol 153(10). https://doi.org/10.1085/jgp.202112923
Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM (2013) MICE models: superior to the HERG model in predicting torsade de pointes. Sci Rep 3(1):2100. https://doi.org/10.1038/srep02100
Krogh-Madsen T, Jacobson AF, Ortega FA, Christini DJ (2017) Global optimization of ventricular myocyte model to multi-variable objective improves predictions of drug-induced Torsades de Pointes. Front Physiol 8. https://doi.org/10.3389/fphys.2017.01059
Kügler P, Erhardt AH, Bulelzai MAK (2018) Early afterdepolarizations in cardiac action potentials as mixed mode oscillations due to a folded node singularity. PLoS One 13(12):e0209498. https://doi.org/10.1371/journal.pone.0209498
Lee W, Windley MJ, Perry MD, Vandenberg JI, Hill AP (2019) Protocol-dependent differences in IC50 values measured in human ether-á-go-go–related gene assays occur in a predictable way and can be used to quantify state preference of drug binding. Mol Pharmacol 95(5):537–550. https://doi.org/10.1124/mol.118.115220
Lei CL, Clerx M, Beattie KA, Melgari D, Hancox JC, Gavaghan DJ, Polonchuk L, Wang K, Mirams GR (2019a) Rapid characterization of hERG channel kinetics II: temperature dependence. Biophys J 117(12):2455–2470. https://doi.org/10.1016/j.bpj.2019.07.030
Lei CL, Clerx M, Gavaghan DJ, Polonchuk L, Mirams GR, Wang K (2019b) Rapid characterization of hERG channel kinetics I: using an automated high-throughput system. Biophys J 117(12):2438–2454. https://doi.org/10.1016/j.bpj.2019.07.029
Lester RM (2021) Update on ICH E14/S7B cardiac safety regulations: the expanded role of preclinical assays and the “double-negative” scenario. Clin Pharmacol Drug Dev 10(9):964–973. https://doi.org/10.1002/cpdd.1003
Li Z, Dutta S, Sheng J, Tran PN, Wu W, Colatsky T (2016) A temperature dependent in silico model of the human ether-à-go-go-related (hERG) gene channel. J Pharmacol Toxicol Methods 81:233–239. https://doi.org/10.1016/j.vascn.2016.05.005
Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, Mdluli T, Strauss DG, Colatsky T (2017) Improving the in silico assessment of proarrhythmia risk by combining hERG (human Ether-à-go-go-related gene) channel–drug binding kinetics and multichannel pharmacology. Circulation 10(2):e004628. https://doi.org/10.1161/CIRCEP.116.004628
Li Z, Garnett C, Strauss DG (2019a) Quantitative systems pharmacology models for a new international cardiac safety regulatory paradigm: an overview of the CiPA in silico modeling approach. PCPT Pharm Syst Pharmacol psp4.12423. https://doi.org/10.1002/psp4.12423
Li Z, Ridder BJ, Han X, Wu WW, Sheng J, Tran PN, Wu M, Randolph A, Johnstone RH, Mirams GR, Kuryshev Y, Kramer J, Wu C, Crumb WJ, Strauss DG (2019b) Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the Ci PA initiative. Clin Pharmacol Ther 105(2):466–475. https://doi.org/10.1002/cpt.1184
Li Z, Mirams GR, Yoshinaga T, Ridder BJ, Han X, Chen JE, Stockbridge NL, Wisialowski TA, Damiano B, Severi S, Morissette P, Kowey PR, Holbrook M, Smith G, Rasmusson RL, Liu M, Song Z, Qu Z, Leishman DJ, Steidl-Nichols J, Rodriguez B, Bueno-Orovio A, Zhou X, Passini E, Edwards AG, Morotti S, Ni H, Grandi E, Clancy CE, Vandenberg J, Hill A, Nakamura M, Singer T, Polonchuk L, Greiter-Wilke A, Wang K, Nave S, Fullerton A, Sobie EA, Paci M, Musuamba Tshinanu F, Strauss DG (2020) General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in silico strategy. Clin Pharmacol Ther 107(1):102–111. https://doi.org/10.1002/cpt.1647
Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC, Wu JC (2013) Drug screening using a library of human induced pluripotent stem cell–derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127(16):1677–1691. https://doi.org/10.1161/CIRCULATIONAHA.113.001883
Liu MB, Vandersickel N, Panfilov AV, Qu Z (2019) R-from-t as a common mechanism of arrhythmia initiation in long qt syndromes. Circ Arrhythm Electrophysiol 12(12):e007571
Loewe S, Muischnek H (1926) Über Kombinationswirkungen. Arch Exp Pathol Pharmakol 114(5-6):313–326. https://doi.org/10.1007/BF01952257
Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for Torsades de Pointes associated with cardiovascular drugs. JAMA 270(21):2590–2597. https://doi.org/10.1001/jama.1993.03510210076031
Mangold KE, Wang W, Johnson EK, Bhagavan D, Moreno JD, Nerbonne JM, Silva JR (2021) Identification of structures for ion channel kinetic models. PLoS Comput Biol 17(8). https://doi.org/10.1371/journal.pcbi.1008932
Mann SA, Imtiaz M, Winbo A, Rydberg A, Perry MD, Couderc JP, Polonsky B, McNitt S, Zareba W, Hill AP, Vandenberg JI (2016) Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. J Mol Cell Cardiol 100:25–34. https://doi.org/10.1016/j.yjmcc.2016.09.011
McMillan B, Gavaghan DJ, Mirams GR (2017) Early after depolarisation tendency as a simulated pro-arrhythmic risk indicator. Toxicol Res 6(6):912–921. https://doi.org/10.1039/C7TX00141J
Mirams GR, Noble D (2011) Is it time for in silico simulation of drug cardiac side effects? Ann N Y Acad Sci 1245(1):44–47
Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D (2011) Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk. Cardiovasc Res 91(1):53–61. https://doi.org/10.1093/cvr/CVR044
Mirams GR, Davies MR, Cui Y, Kohl P, Noble D (2012) Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol 167(5):932–945. https://doi.org/10.1111/j.1476-5381.2012.02020.x
Mirams GR, Davies MR, Brough SJ, Bridgland-Taylor MH, Cui Y, Gavaghan DJ, Abi-Gerges N (2014) Prediction of thorough QT study results using action potential simulations based on ion channel screens. J Pharmacol Toxicol Methods 70(3):246–254. https://doi.org/10.1016/j.vascn.2014.07.002
Mirams GR, Pathmanathan P, Gray RA, Challenor P, Clayton RH (2016) White paper: uncertainty and variability in computational and mathematical models of cardiac physiology. J Physiol. https://doi.org/10.1113/JP271671
Mistry HB (2018) Complex versus simple models: ion-channel cardiac toxicity prediction. Peer J 6(2):e4352. https://doi.org/10.7717/peerj.4352
Mohr M, Chambard JM, Ballet V, Schmidt F (2022) Accurate in silico simulation of the rabbit Purkinje fiber electrophysiological assay to facilitate early pharmaceutical cardiosafety assessment: dream or reality? J Pharmacol Toxicol Methods 115:107172. https://doi.org/10.1016/J.VASCN.2022.107172
Montnach J, Baró I, Charpentier F, De Waard M, Loussouarn G (2021) Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. EP Europace 23(7):1124–1136. https://doi.org/10.1093/europace/euab043
Moreno JD, Lewis TJ, Clancy CE (2016) Parameterization for in-silico modeling of ion channel interactions with drugs. PLoS One 11(3):e0150761. https://doi.org/10.1371/journal.pone.0150761
Morotti S, Liu C, Hegyi B, Ni H, Iseppe AF, Wang L, Pritoni M, Ripplinger CM, Bers DM, Edwards AG, Grandi E (2021) Quantitative cross-species translators of cardiac myocyte electrophysiology: model training, experimental validation, and applications. Sci Adv 7(47). https://doi.org/10.1126/sciadv.abg0927
Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, Cherry EM, Clayton R, Fenton FH, Garny A, Heidenreich E, Land S, Maleckar M, Pathmanathan P, Plank G, Rodríguez JF, Roy I, Sachse FB, Seemann G, Skavhaug O, Smith NP (2011) Verification of cardiac tissue electrophysiology simulators using an N-version benchmark. Philos Trans R Soc A Math Phys Eng Sci 369(1954):4331–4351. https://doi.org/10.1098/rsta.2011.0139
Noble D (1962) A modification of the Hodgkin–Huxley equations applicable to Purkinje fibre action and pacemaker potentials. J Physiol 160(2):317
Noble D (2008) Computational models of the heart and their use in assessing the actions of drugs. J Pharmacol Sci 107(2):107–117. https://doi.org/10.1254/jphs.CR0070042
Noble D, Garny A, Noble PJ (2012) How the Hodgkin–Huxley equations inspired the Cardiac Physiome Project. J Physiol 590(11):2613–2628. https://doi.org/10.1113/jphysiol.2011.224238
O’Hara T, Virág L, Varró A, Rudy Y (2011) Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7(5):e1002061. https://doi.org/10.1371/journal.pcbi.1002061
Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M (2011) A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J Chem Inf Model 51(2):483–492. https://doi.org/10.1021/ci100423z
Okada JI, Yoshinaga T, Kurokawa J, Washio T, Furukawa T, Sawada K, Sugiura S, Hisada T (2015) Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. Sci Adv 1(4). https://doi.org/10.1126/sciadv.1400142
Okada JI, Yoshinaga T, Kurokawa J, Washio T, Furukawa T, Sawada K, Sugiura S, Hisada T (2018) Arrhythmic hazard map for a 3D whole-ventricle model under multiple ion channel block. Br J Pharmacol 175(17):3435–3452. https://doi.org/10.1111/bph.14357
Okada JI, Yoshinaga T, Washio T, Sawada K, Sugiura S, Hisada T (2021) Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: a simulation study. Clin Transl Sci 14(3):1092–1100. https://doi.org/10.1111/cts.12976
Ortega FA, Grandi E, Krogh-Madsen T, Christini DJ (2018) Applications of dynamic clamp to cardiac arrhythmia research: role in drug target discovery and safety pharmacology testing. Front Physiol 8(January):1–8. https://doi.org/10.3389/fphys.2017.01099
Park JS, Jeon JY, Yang JH, Kim MG (2019) Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative. Transl Clin Pharmacol 27(1):12. https://doi.org/10.12793/tcp.2019.27.1.12
Passini E, Britton OJ, Lu HR, Rohrbacher J, Hermans AN, Gallacher DJ, Greig RJH, Bueno-Orovio A, Rodriguez B (2017) Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. Front Physiol 8:1–15. https://doi.org/10.3389/fphys.2017.00668
Passini E, Trovato C, Morissette P, Sannajust F, Bueno-Orovio A, Rodriguez B (2019) Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias. Br J Pharmacol 176(19):3819–3833. https://doi.org/10.1111/bph.14786
Pathmanathan P, Gray RA (2018) Validation and trustworthiness of multiscale models of cardiac electrophysiology. Front Physiol 9:106. https://doi.org/10.3389/fphys.2018.00106
Peirlinck M, Sahli Costabal F, Kuhl E (2021) Sex differences in drug-induced arrhythmogenesis. Front Physiol 12:1245. https://doi.org/10.3389/fphys.2021.708435
Perissinotti LL, Guo J, De Biase PM, Clancy CE, Duff HJ, Noskov SY (2015) Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel. Biophys J 108(6):1414–1424. https://doi.org/10.1016/j.bpj.2014.12.056
Polak S, Wiśniowska B, Brandys J (2009) Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs’ cardiotoxic properties. https://doi.org/10.1002/jat.1395
Pollard C, Abi Gerges N, Bridgland-Taylor M, Easter A, Hammond T, Valentin JP (2010) An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159(1):12–21. https://doi.org/10.1111/j.1476-5381.2009.00207.x
Qu Z, Hu G, Garfinkel A, Weiss JN (2014) Nonlinear and stochastic dynamics in the heart. Phys Rep 543(2):61–162. https://doi.org/10.1016/j.physrep.2014.05.002
Raphel F, De Korte T, Lombardi D, Braam S, Gerbeau JF (2020) A greedy classifier optimization strategy to assess ion channel blocking activity and pro-arrhythmia in hiPSC-cardiomyocytes. PLoS Comput Biol 16(9):e1008203. https://doi.org/10.1371/journal.pcbi.1008203
RECOVERY Collaborative Group (2020) Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 383(21):2030–2040. https://doi.org/10.1056/NEJMoa2022926
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32–45. https://doi.org/10.1016/S0008-6363(02)00846-5
Romero L, Cano J, Gomis-Tena J, Trenor B, Sanz F, Pastor M, Saiz J (2018) In silico QT and APD prolongation assay for early screening of drug-induced proarrhythmic risk. J Chem Inf Model 58(4):867–878. https://doi.org/10.1021/acs.jcim.7b00440
Rudy Y, Silva JR (2006) Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys 39(1):57–116. https://doi.org/10.1017/S0033583506004227
Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167(3):292–300. https://doi.org/10.1016/j.ahj.2013.11.004
Sahli Costabal F, Yao J, Kuhl E (2018) Predicting drug-induced arrhythmias by multiscale modeling. Int J Num Methods Biomed Eng 34(5):e2964. https://doi.org/10.1002/cnm.2964
Sahli Costabal F, Matsuno K, Yao J, Perdikaris P, Kuhl E (2019) Machine learning in drug development: characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and uncertainty quantification. Comput Methods Appl Mech Eng 348:313–333. https://doi.org/10.1016/j.cma.2019.01.033
Sahli-Costabal F, Seo K, Ashley E, Kuhl E (2020) Classifying drugs by their arrhythmogenic risk using machine learning. Biophys J 118(5):1165–1176. https://doi.org/10.1016/j.bpj.2020.01.012
Senn S (2005) Dichotomania: an obsessive compulsive disorder that is badly affecting the quality of analysis of pharmaceutical trials. In: Proceedings of the International Statistical Institute, 55th Session, Sydney. https://www.isi-web.org/isi.cbs.nl/iamamember/CD6-Sydney2005/ISI2005_Papers/398.pdf. Accessed 12 Oct 2022
Shannon TR, Wang F, Puglisi J, Weber C, Bers DM (2004) A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophys J 87(5):3351–3371. https://doi.org/10.1529/biophysj.104.047449
Starmer CF, Courtney KR (1986) Modeling ion channel blockade at guarded binding sites: application to tertiary drugs. Am J Phys Heart Circ Phys 251(4):H848–H856. https://doi.org/10.1152/ajpheart.1986.251.4.H848
Starmer CF, Grant AO (1985) Phasic ion channel blockade. A kinetic model and parameter estimation procedure. Mol Pharmacol 28(4):348–356. https://molpharm.aspetjournals.org/content/28/4/348.full.pdf. Accessed 12 Oct 2022
Starmer CF, Nesterenko VV, Gilliam FR, Grant AO (1990) Use of ionic currents to identify and estimate parameters in models of channel blockade. Am J Physiol Heart Circ Physiol 259(2:28–22. https://doi.org/10.1152/ajpheart.1990.259.2.h626
Starmer CF, Lastra AA, Nesterenko VV, Grant AO (1991) Proarrhythmic response to sodium channel blockade: theoretical model and numerical experiments. Circulation 84(3):1364–1377. https://doi.org/10.1161/01.CIR.84.3.1364
Sutanto H, Heijman J (2020) Beta-adrenergic receptor stimulation modulates the cellular proarrhythmic effects of chloroquine and azithromycin. Front Physiol 11:1346. https://doi.org/10.3389/fphys.2020.587709
TeBay C, McArthur JR, Mangala M, Kerr N, Heitmann S, Perry MD, Windley MJ, Vandenberg JI, Hill AP (2022) Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. Br J Pharmacol 179(11):2631–2646. https://doi.org/10.1111/bph.15757
Thomet U, Amuzescu B, Knott T, Mann SA, Mubagwa K, Radu BM (2021) Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. Eur J Pharmacol 913:174632. https://doi.org/10.1016/J.EJPHAR.2021.174632
Tomek J, Bueno-Orovio A, Passini E, Zhou X, Minchole A, Britton O, Bartolucci C, Severi S, Shrier A, Virag L, Varro A, Rodriguez B (2019) Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. eLife 8. https://doi.org/10.7554/eLife.48890
Uzelac I, Kaboudian A, Iravanian S, Siles-Paredes JG, Gumbart JC, Ashikaga H, Bhatia N, Gilmour RF, Cherry EM, Fenton FH (2021) Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations. Heart Rhythm O2 2(4):394–404. https://doi.org/10.1016/j.hroo.2021.06.008
Vandenberg JI, Varghese A, Lu Y, Bursill JA, Mahaut-Smith MP, Huang CL (2006) Temperature dependence of human ether-à-go-go-related gene K+ currents. Am J Phys Cell Phys 291(1):C165–C175. https://doi.org/10.1152/ajpcell.00596.2005
Varshneya M, Irurzun-Arana I, Campana C, Dariolli R, Gutierrez A, Pullinger TK, Sobie EA (2021) Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions. PCPT Pharm Syst Pharmacol 10(2):100–107. https://doi.org/10.1002/psp4.12573
Wang G, Lu CJ, Trafford AW, Tian X, Flores HM, Maj P, Zhang K, Niu Y, Wang L, Du Y, Ji X, Xu Y, Wu L, Li D, Herring N, Paterson D, Huang CL, Zhang H, Lei M, Hao G (2021) Electrophysiological and proarrhythmic effects of hydroxychloroquine challenge in guinea-pig hearts. ACS Pharmacol Transl Sci 4(5):1639–1653. https://doi.org/10.1021/acsptsci.1c00166
Whiteley JP (2020) An evaluation of some assumptions underpinning the bidomain equations of electrophysiology. Math Med Biol J IMA 37(2):262–302. https://doi.org/10.1093/imammb/dqz014
Whittaker DG, Clerx M, Lei CL, Christini DJ, Mirams GR (2020) Calibration of ionic and cellular cardiac electrophysiology models. WIREs Syst Biol Med 12(4):1–51. https://doi.org/10.1002/wsbm.1482
Whittaker DG, Capel RA, Hendrix M, Chan XHS, Herring N, White NJ, Mirams GR, Burton RAB (2021) Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine. R Soc Open Sci 8(4). https://doi.org/10.1098/RSOS.210235
Williams G, Mirams GR (2015) A web portal for in-silico action potential predictions. J Pharmacol Toxicol Methods 75:10–16
Windley MJ, Mann SA, Vandenberg JI, Hill AP (2016) Temperature effects on kinetics of KV11.1 drug block have important consequences for in silico proarrhythmic risk prediction. Mol Pharmacol 90(1):1–11. https://doi.org/10.1124/mol.115.103127
Windley MJ, Abi-Gerges N, Fermini B, Hancox JC, Vandenberg JI, Hill AP (2017) Measuring kinetics and potency of hERG block for CiPA. J Pharmacol Toxicol Methods. https://doi.org/10.1016/j.vascn.2017.02.017
Windley MJ, Lee W, Vandenberg JI, Hill AP (2018) The temperature dependence of kinetics associated with drug block of hERG channels is compound-specific and an important factor for proarrhythmic risk prediction. Mol Pharmacol 94(1):760–769. https://doi.org/10.1124/mol.117.111534
Wiśniowska B, Polak S (2016a) Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity. Drug Discov Today. https://doi.org/10.1016/j.drudis.2016.09.027
Wiśniowska B, Polak S (2016b) The role of interaction model in simulation of drug interactions and QT prolongation. Curr Pharmacol Rep 2(6):339–344. https://doi.org/10.1007/s40495-016-0075-9
Woosley RL, Black K, Heise CW, Romero K (2018) CredibleMeds.org: what does it offer? Trends Cardiovasc Med 28(2):94–99. https://doi.org/10.1016/j.tcm.2017.07.010
Xie Y, Sato D, Garfinkel A, Qu Z, Weiss JN (2010) So little source, so much sink: requirements for afterdepolarizations to propagate in tissue. Biophys J 99(5):1408–1415. https://doi.org/10.1016/j.bpj.2010.06.042
Yang PC, Clancy CE (2012) In silico prediction of sex-based differences in human susceptibility to cardiac ventricular tachyarrhythmias. Front Physiol 3:360. https://doi.org/10.3389/fphys.2012.00360
Yang PC, Kurokawa J, Furukawa T, Clancy CE (2010) Acute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation study. PLoS Comput Biol 6(1):e1000658. https://doi.org/10.1371/journal.pcbi.1000658
Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM (2014) Screening for acute i kr block is insufficient to detect Torsades de Pointes liability: role of late sodium current. Circulation 130(3):224–234. https://doi.org/10.1161/CIRCULATIONAHA.113.007765
Zemzemi N, Bernabeu MO, Saiz J, Cooper J, Pathmanathan P, Mirams GR, Pitt-Francis J, Rodriguez B (2013) Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br J Pharmacol 168(3):718–733. https://doi.org/10.1111/j.1476-5381.2012.02200.x
Zhao Y, Zhang J, Zheng K, Thai S, Simpson RJ, Kinlaw AC, Xu Y, Wei J, Cui X, Buse JB, Stürmer T, Wang T (2022) Serious cardiovascular adverse events associated with hydroxychloroquine/chloroquine alone or with azithromycin in patients with COVID-19: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS). Drugs Real World Outcomes 9(2):231–241. https://doi.org/10.1007/s40801-022-00300-y
Zhou P, Babcock J, Liu L, Li M, Gao Z (2011) Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules. Acta Pharmacol Sin 32(6):781–788. https://doi.org/10.1038/aps.2011.70
Acknowledgments
The author gratefully acknowledges support from the Wellcome Trust (grant number 212203/Z/18/Z). He would also like to acknowledge helpful discussions with his research team based at the University of Nottingham, and collaborators and members of the CiPA Steering Committee and working groups.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Mirams, G.R. (2023). Computational Cardiac Safety Testing. In: Hock, F.J., Gralinski, M.R., Pugsley, M.K. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Cham. https://doi.org/10.1007/978-3-030-73317-9_137-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-73317-9_137-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-73317-9
Online ISBN: 978-3-030-73317-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences